Sophiris Bio Receives Feedback From European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design; Co. Expects That Data From Single Phase 3 Trial, If Successful, Will Be Sufficient To Support Marketing Approval In Europe
Benzinga Newsdesk